Marvin Antonio Soriano Ursúa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marvin Antonio Soriano Ursúa has a total of 334 co-authors. Here are the top co-authors by number of shared publications:
- Eunice Dalet Farfán-García
Academia de Bioquímica, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Mexico City 11340, Mexico
26 shared publications - José Guadalupe Trujillo Ferrara
Laboratorio de Bioquímica, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Col. Casco de Santo Tomas, Alc. Miguel Hidalgo, Mexico City 11340, Mexico
17 shared publications José G. Trujillo-Ferrara
Departamento de Bioquímica, Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, Alc. Miguel Hidalgo, 11340 Mexico City, Mexico
14 shared publications- Jose Antonio Morales Gonzalez
Laboratorio de Medicina de Conservación, Escuela Superior de Medicina del Instituto Politécnico Nacional, Plan de San Luis y Diaz Mirón s/n, Mexico City 11340, Mexico
10 shared publications - Itzia I. Padilla-Martínez
Laboratorio de Química Supramolecular y Nanociencias, Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional, Avenida Acueducto s/n, Barrio la Laguna Ticomán, Mexico City 07340, Mexico
9 shared publications José Correa-Basurto
Laboratorio de Modelado Molecular y Diseño de Fármacos, Escuela Superior de Medicina, Instituto Politécnico Nacional, 11340 México City, DF, Mexico
9 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1588
To Add B, or Not to Add B: That Is the Question
Incorporating boron (B) into bioactive molecules is not a question in nature
- 8 October 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (10) , 1588
Open AccessTo Add B, or Not to Add B: That Is the Question
Incorporating boron (B) into bioactive molecules is not a question in nature
- 13 September 2026
- Published by Springer Nature
- p. 1-29
Pharmacodynamics of Boronic Acids and Boronates
- Open Access
- 10 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1437
Synthetic Fructoborate Administration: Effects on Cardiac Remodeling and Extracardiac Responses in Isoproterenol-Induced Cardiac Hypertrophy
Background: Synthetic fructoborate (sFB) is a boron-containing compound with reported biological effects, but its influence on cardiac remodeling remains poorly characterized. Objective: To evaluate the cardiac effects of short-term sFB administration and compare cardiac and extracardiac responses when sFB was administered before or after isoproterenol-induced cardiac hypertrophy. Methods: Male BALB/c mice received sFB (17, 34, or 68 mg/kg) for 3 days to assess cardiac morphology, p38 MAPK phosphorylation, Atrial Natriuretic Peptide (ANP) and Natriuretic Peptide B (BNP) mRNA expression, and oxidative stress-related markers. In a second experiment, cardiac hypertrophy was induced with isoproterenol (50 mg/kg, intraperitoneally, for 7 days), and sFB (34 mg/kg for 3 days) was administered before or after hypertrophy induction. Cardiac and extracardiac histological, molecular, and biochemical responses were evaluated. Results: Short-term sFB administration did not produce a consistent pattern of cardiac injury. The p-p38 MAPK/p38 MAPK ratio decreased, and 17 mg/kg sFB increased plasma glutathione (GSH) levels. When administered after hypertrophy induction, sFB reduced left ventricular wall thickness, cardiomyocyte area, and collagen I and III deposition and increased ventricular lumen area. Administration before isoproterenol exposure produced a different response, with some preserved structural parameters but persistent collagen deposition and increased expression of remodeling-associated genes. Extracardiac responses were heterogeneous and tissue-dependent, with notable hepatic alterations under some conditions. Conclusions: The effects of sFB on isoproterenol-induced cardiac hypertrophy depended on the timing of administration, with more consistent attenuation of structural remodeling when administered after hypertrophy induction. Further studies are required to establish its long-term safety, pharmacokinetics, and potential therapeutic relevance.
- 10 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1437
Open AccessSynthetic Fructoborate Administration: Effects on Cardiac Remodeling and Extracardiac Responses in Isoproterenol-Induced Cardiac Hypertrophy
Background: Synthetic fructoborate (sFB) is a boron-containing compound with reported biological effects, but its influence on cardiac remodeling remains poorly characterized. Objective: To evaluate the cardiac effects of short-term sFB administration and compare cardiac and extracardiac responses when sFB was administered before or after isoproterenol-induced cardiac hypertrophy. Methods: Male BALB/c mice received sFB (17, 34, or 68 mg/kg) for 3 days to assess cardiac morphology, p38 MAPK phosphorylation, Atrial Natriuretic Peptide (ANP) and Natriuretic Peptide B (BNP) mRNA expression, and oxidative stress-related markers. In a second experiment, cardiac hypertrophy was induced with isoproterenol (50 mg/kg, intraperitoneally, for 7 days), and sFB (34 mg/kg for 3 days) was administered before or after hypertrophy induction. Cardiac and extracardiac histological, molecular, and biochemical responses were evaluated. Results: Short-term sFB administration did not produce a consistent pattern of cardiac injury. The p-p38 MAPK/p38 MAPK ratio decreased, and 17 mg/kg sFB increased plasma glutathione (GSH) levels. When administered after hypertrophy induction, sFB reduced left ventricular wall thickness, cardiomyocyte area, and collagen I and III deposition and increased ventricular lumen area. Administration before isoproterenol exposure produced a different response, with some preserved structural parameters but persistent collagen deposition and increased expression of remodeling-associated genes. Extracardiac responses were heterogeneous and tissue-dependent, with notable hepatic alterations under some conditions. Conclusions: The effects of sFB on isoproterenol-induced cardiac hypertrophy depended on the timing of administration, with more consistent attenuation of structural remodeling when administered after hypertrophy induction. Further studies are required to establish its long-term safety, pharmacokinetics, and potential therapeutic relevance.
- Open Access
- 20 July 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (3) , 62
Potential Interactions of Active Compounds of Morinda citrifolia (Noni) on Targets Involved in Human Diseases
Morinda citrifolia (Noni) is well known as a plant with therapeutic potential and is also attractive to the food and cosmetic industries. Traditional medicine supports its use, mainly for the treatment of metabolic disorders and chronic inflammation but also for certain types of cancer. Noni has been the subject of considerable interest within the scientific community due to its purported health benefits. However, despite its growing popularity and extensive traditional use, significant gaps remain in the empirical understanding of its properties, mechanisms, and potential applications. To understand its biological activity, particular attention has been given to several chemical compounds present in its leaves and fruits, as they have been identified as bioactive agents. Moreover, several studies support the idea that specific flavonoids and anthraquinones from noni act on enzymes and transporters associated with glucose and lipid metabolism in humans. Its involvement in cardiovascular, neurological, metabolic, and inflammatory regulation across several high-burden diseases expands the potential medical applications of noni. This narrative review presents the current state of knowledge, highlighting preclinical studies that suggest the mechanisms of action underlying the observed effects, including theoretical approaches proposing specific interactions between noni compounds and proteins associated with human diseases as potential therapeutic targets. It also identifies areas where information remains insufficient and proposes future research directions for pharmacological applications, including the need for additional clinical studies and more comprehensive pharmacokinetic and toxicological evaluations.
- 20 July 2026
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 94 (3) , 62
Open AccessPotential Interactions of Active Compounds of Morinda citrifolia (Noni) on Targets Involved in Human Diseases
Morinda citrifolia (Noni) is well known as a plant with therapeutic potential and is also attractive to the food and cosmetic industries. Traditional medicine supports its use, mainly for the treatment of metabolic disorders and chronic inflammation but also for certain types of cancer. Noni has been the subject of considerable interest within the scientific community due to its purported health benefits. However, despite its growing popularity and extensive traditional use, significant gaps remain in the empirical understanding of its properties, mechanisms, and potential applications. To understand its biological activity, particular attention has been given to several chemical compounds present in its leaves and fruits, as they have been identified as bioactive agents. Moreover, several studies support the idea that specific flavonoids and anthraquinones from noni act on enzymes and transporters associated with glucose and lipid metabolism in humans. Its involvement in cardiovascular, neurological, metabolic, and inflammatory regulation across several high-burden diseases expands the potential medical applications of noni. This narrative review presents the current state of knowledge, highlighting preclinical studies that suggest the mechanisms of action underlying the observed effects, including theoretical approaches proposing specific interactions between noni compounds and proteins associated with human diseases as potential therapeutic targets. It also identifies areas where information remains insufficient and proposes future research directions for pharmacological applications, including the need for additional clinical studies and more comprehensive pharmacokinetic and toxicological evaluations.
- Open Access
- 14 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4372
Nutrient-Sensitive Epigenetic Modifiers as Candidate Biomarkers of Metabolic Dysfunction in Obesity: A Nutrigenomic Review
Obesity is a complex metabolic disorder resulting from interactions among genetic, environmental, and dietary factors. Traditional clinical markers may provide limited insight into the biochemical mechanisms that link nutrition and metabolic dysfunction; in this context, the epigenetic mechanisms through which nutrients modulate gene expression are central to understanding metabolic homeostasis. This review summarizes the published evidence on nutrient-driven epigenetic processes in obesity, focusing on DNA methyl donors, such as folate, vitamin B12, choline, betaine, serine, and methionine, and their effects on methylation and DNA methyltransferase activity. Metabolites such as acetyl-CoA, NAD+, and short-chain fatty acids (SCFAs) can also influence histone modifications, while diet-responsive microRNAs can regulate networks involved in adipogenesis, lipid metabolism, inflammation, and insulin signaling. Recent studies have identified epigenetic signatures associated with adiposity and metabolic traits, many of which are linked to the risk of cardiometabolic disease. This review is structured around the concept that nutrient-sensitive epigenetic mechanisms act as candidate biomarkers, linking dietary exposure to metabolic dysfunction. Recent evidence supports the idea that nutrient–epigenetic variation could complement traditional metabolic evaluations by offering mechanistic insight and translational direction. These findings suggest that nutrient-sensitive epigenetic mechanisms are biologically plausible candidate biomarker layers; however, their clinical implementation is currently limited by issues including tissue specificity, reproducibility, and the need for prospective validation.
- 14 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (10) , 4372
Open AccessNutrient-Sensitive Epigenetic Modifiers as Candidate Biomarkers of Metabolic Dysfunction in Obesity: A Nutrigenomic Review
Obesity is a complex metabolic disorder resulting from interactions among genetic, environmental, and dietary factors. Traditional clinical markers may provide limited insight into the biochemical mechanisms that link nutrition and metabolic dysfunction; in this context, the epigenetic mechanisms through which nutrients modulate gene expression are central to understanding metabolic homeostasis. This review summarizes the published evidence on nutrient-driven epigenetic processes in obesity, focusing on DNA methyl donors, such as folate, vitamin B12, choline, betaine, serine, and methionine, and their effects on methylation and DNA methyltransferase activity. Metabolites such as acetyl-CoA, NAD+, and short-chain fatty acids (SCFAs) can also influence histone modifications, while diet-responsive microRNAs can regulate networks involved in adipogenesis, lipid metabolism, inflammation, and insulin signaling. Recent studies have identified epigenetic signatures associated with adiposity and metabolic traits, many of which are linked to the risk of cardiometabolic disease. This review is structured around the concept that nutrient-sensitive epigenetic mechanisms act as candidate biomarkers, linking dietary exposure to metabolic dysfunction. Recent evidence supports the idea that nutrient–epigenetic variation could complement traditional metabolic evaluations by offering mechanistic insight and translational direction. These findings suggest that nutrient-sensitive epigenetic mechanisms are biologically plausible candidate biomarker layers; however, their clinical implementation is currently limited by issues including tissue specificity, reproducibility, and the need for prospective validation.
- Open Access
- 25 March 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (4) , 494
Aryl-Boroxazolidones with Low In Vitro Neurotoxicity and Alleviative Effects on MPTP-Induced Parkinsonism in Mice
Parkinson’s disease (PD) is one of the most prevalent and extensively studied neurodegenerative conditions. One of its most challenging clinical manifestations is the emergence of dyskinesias, characterized by involuntary movements that significantly impair patients’ quality of life. Meanwhile, boron, as a trace element, and boron-containing compounds have emerged as active modulators of neurotransmitter systems. To evaluate the effect of aryl-boroxazolidones on parkinsonism, the in vitro neurotoxicity of three boroxazolidones was assessed, along with the effects of two of them in mice with parkinsonism induced by MPTP administration. Two novel compounds demonstrated a limitation of parkinsonism, whereas risperidone reduced the beneficial effect of the tested boroxazolidones. The three boroxazolidones did not induce toxicity in neurons or glial cells at concentrations up to 100 µM. In silico analyses support the ability of BCC to act as ligands of dopamine and serotonin receptors. Taken together, these results suggest that the tested boroxazolidones are promising candidate agents, warranting further exploration for the treatment of PD.
- 25 March 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (4) , 494
Open AccessAryl-Boroxazolidones with Low In Vitro Neurotoxicity and Alleviative Effects on MPTP-Induced Parkinsonism in Mice
Parkinson’s disease (PD) is one of the most prevalent and extensively studied neurodegenerative conditions. One of its most challenging clinical manifestations is the emergence of dyskinesias, characterized by involuntary movements that significantly impair patients’ quality of life. Meanwhile, boron, as a trace element, and boron-containing compounds have emerged as active modulators of neurotransmitter systems. To evaluate the effect of aryl-boroxazolidones on parkinsonism, the in vitro neurotoxicity of three boroxazolidones was assessed, along with the effects of two of them in mice with parkinsonism induced by MPTP administration. Two novel compounds demonstrated a limitation of parkinsonism, whereas risperidone reduced the beneficial effect of the tested boroxazolidones. The three boroxazolidones did not induce toxicity in neurons or glial cells at concentrations up to 100 µM. In silico analyses support the ability of BCC to act as ligands of dopamine and serotonin receptors. Taken together, these results suggest that the tested boroxazolidones are promising candidate agents, warranting further exploration for the treatment of PD.
- Open Access
Antimutagenic and Anticarcinogenic Evidence of the Genus Ficus L.
Among the most important species of Ficus L. genus are F. deltoidea, F. exasperata, F. sycomorus, F. religiosa, F. microcarpa, F. hirta Vahl., F. benghalensis, F. racemosa, F. elastica, and F. carica. The genus has more than 30 traditional ethnomedicinal uses, attributed to the combination of different bioactive compounds, including flavonoids, (flavanols, flavones, flavonols, isoflavones, chalcones, anthocyanins), phenolic acids (hydroxycinnamic acids, hydroxybenzoic acids), terpenes (triterpenes, tetraterpenes, diterpenes, sesquiterpenes, monoterpenes), phytosterols, coumarins, hydroxybenzoates, phenylpropanoids, chlorins, pheophytins, megastigmans, chitinases, organic acids, fatty acids, amino acids, alkaloids, and glycosides. With this in mind, the objective of this manuscript was to conduct a scientific search in the main electronic databases (PubMed, SciELO, Latindex, Redalyc, BiologyBrowser, ScienceResearch, ScienceDirect, World Wide Science, Web of Science, Academic Journals, Etnobotany, Scopus, and Google Scholar) to gather information on published research regarding the genoprotective potential of the Ficus L. genus. Unlike most scientific articles, which primarily describe the individual characteristics and properties of each species, this document compiles the largest number of studies (in vitro and in vivo) on Ficus plants described by different authors. Thus, we aim to promote more detailed scientific research and expand studies on the protective capacity of these angiosperm plants to the genetic material.
Open AccessAntimutagenic and Anticarcinogenic Evidence of the Genus Ficus L.
Among the most important species of Ficus L. genus are F. deltoidea, F. exasperata, F. sycomorus, F. religiosa, F. microcarpa, F. hirta Vahl., F. benghalensis, F. racemosa, F. elastica, and F. carica. The genus has more than 30 traditional ethnomedicinal uses, attributed to the combination of different bioactive compounds, including flavonoids, (flavanols, flavones, flavonols, isoflavones, chalcones, anthocyanins), phenolic acids (hydroxycinnamic acids, hydroxybenzoic acids), terpenes (triterpenes, tetraterpenes, diterpenes, sesquiterpenes, monoterpenes), phytosterols, coumarins, hydroxybenzoates, phenylpropanoids, chlorins, pheophytins, megastigmans, chitinases, organic acids, fatty acids, amino acids, alkaloids, and glycosides. With this in mind, the objective of this manuscript was to conduct a scientific search in the main electronic databases (PubMed, SciELO, Latindex, Redalyc, BiologyBrowser, ScienceResearch, ScienceDirect, World Wide Science, Web of Science, Academic Journals, Etnobotany, Scopus, and Google Scholar) to gather information on published research regarding the genoprotective potential of the Ficus L. genus. Unlike most scientific articles, which primarily describe the individual characteristics and properties of each species, this document compiles the largest number of studies (in vitro and in vivo) on Ficus plants described by different authors. Thus, we aim to promote more detailed scientific research and expand studies on the protective capacity of these angiosperm plants to the genetic material.
- Open Access
- 10 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11914
Aqueous Extract of Bacopa procumbens and the NAPEL Formulation Mitigate MPTP-Induced Neurotoxicity via Nrf2/HSF1/HIF-1α Signaling in a Parkinson’s Disease Model
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron degeneration in the substantia nigra and striatum. Current treatments are largely palliative and frequently associated with adverse effects. This study aimed to evaluate the neuroprotective potential of an aqueous extract of Bacopa procumbens (B. procumbens) and the NAPEL formulation—composed of five neuroactive compounds (Naringenin, Apigenin, Paeoniflorin, (−)-Epicatechin, and Lupeol)—in a murine model of MPTP-induced parkinsonism. Behavioral, histological, and molecular parameters were examined to elucidate underlying mechanisms of neuroprotection. Male mice received MPTP to induce parkinsonism, followed by oral administration of B. procumbens extract or NAPEL. Motor function was assessed through open-field-related parameters. Substantia nigra neuronal morphology was analyzed histologically. Molecular analyses focused on the Keap1/Nrf2/ARE pathway, HSF1, HIF-1α, antioxidant enzymes, and lipid peroxidation. Additionally, in silico analyses (GeneMANIA, STRING) were performed to explore regulatory networks associated with Nrf2, HSF1, and HIF-1α. The aqueous extract significantly improved motor performance, increased rearing events, enhanced central exploration, and increased total distance traveled. It preserved neuronal number and soma diameter in the substantia nigra. Molecularly, the extract activated the Keap1/Nrf2/ARE axis and induced HSF1 and HIF-1α, accompanied by increased SOD-1, CAT, and GSR expression and reduced lipid peroxidation. NAPEL also produced behavioral and histological improvements but did not activate Nrf2, HSF1, or HIF-1α nor notably elevate antioxidant enzymes, except for CAT in the striatum. In silico analyses identified Nrf2, HSF1, and HIF-1α as central nodes integrating oxidative stress, proteostasis, hypoxia, inflammation, and apoptotic responses. These findings support the neuroprotective potential of both B. procumbens aqueous extract and the NAPEL formulation, highlighting their value as promising therapeutic candidates for Parkinson’s disease.
- 10 December 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (24) , 11914
Open AccessAqueous Extract of Bacopa procumbens and the NAPEL Formulation Mitigate MPTP-Induced Neurotoxicity via Nrf2/HSF1/HIF-1α Signaling in a Parkinson’s Disease Model
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron degeneration in the substantia nigra and striatum. Current treatments are largely palliative and frequently associated with adverse effects. This study aimed to evaluate the neuroprotective potential of an aqueous extract of Bacopa procumbens (B. procumbens) and the NAPEL formulation—composed of five neuroactive compounds (Naringenin, Apigenin, Paeoniflorin, (−)-Epicatechin, and Lupeol)—in a murine model of MPTP-induced parkinsonism. Behavioral, histological, and molecular parameters were examined to elucidate underlying mechanisms of neuroprotection. Male mice received MPTP to induce parkinsonism, followed by oral administration of B. procumbens extract or NAPEL. Motor function was assessed through open-field-related parameters. Substantia nigra neuronal morphology was analyzed histologically. Molecular analyses focused on the Keap1/Nrf2/ARE pathway, HSF1, HIF-1α, antioxidant enzymes, and lipid peroxidation. Additionally, in silico analyses (GeneMANIA, STRING) were performed to explore regulatory networks associated with Nrf2, HSF1, and HIF-1α. The aqueous extract significantly improved motor performance, increased rearing events, enhanced central exploration, and increased total distance traveled. It preserved neuronal number and soma diameter in the substantia nigra. Molecularly, the extract activated the Keap1/Nrf2/ARE axis and induced HSF1 and HIF-1α, accompanied by increased SOD-1, CAT, and GSR expression and reduced lipid peroxidation. NAPEL also produced behavioral and histological improvements but did not activate Nrf2, HSF1, or HIF-1α nor notably elevate antioxidant enzymes, except for CAT in the striatum. In silico analyses identified Nrf2, HSF1, and HIF-1α as central nodes integrating oxidative stress, proteostasis, hypoxia, inflammation, and apoptotic responses. These findings support the neuroprotective potential of both B. procumbens aqueous extract and the NAPEL formulation, highlighting their value as promising therapeutic candidates for Parkinson’s disease.
- Open Access
- 8 December 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (12) , 1711
Boron Bioavailability Revisited: From Plasma-Accessible Species to Microbiota-Accessible Complexes—Implications for Nutritional Essentiality
Boron (B) remains one of the least understood trace elements in human nutrition. Traditionally regarded as non-essential, its biological role has been reevaluated in light of emerging microbiome research. We provide a narrative synthesis of mechanistic, preclinical, and clinical studies to assess whether the colonic actions of B meet accepted criteria for nutritional essentiality. This review revisits B bioavailability through a dual-pathway framework distinguishing plasma-accessible boron (PAB)—small, fully absorbable species with transient systemic effects—from microbiota-accessible boron complexes (MABCs)—indigestible conjugates that reach the colon intact. Evidence indicates that PAB exerts short-term metabolic modulation, whereas MABCs act as prebiotic cofactors that stabilize microbial quorum sensing (autoinducer-2–borate; AI-2B), reinforce the colonic mucus barrier through borate–diol crosslinking, and support host–microbiota symbiosis. Deficiency or low intake of MABCs leads to dysbiosis, barrier fragility, and low-grade inflammation along gut–organ axes—effects reversible by MABC-rich diets. Analytical and clinical tools are proposed to discriminate between PAB and MABC pathways, including fecal B/speciation, AI-2B assays, and mucus-penetration markers. Recognizing B’s essentiality as a microbiota-dependent nutrient reframes its nutritional assessment, guiding future dietary guidelines and prebiotic design toward the microbiome–mucus interface.
- 8 December 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (12) , 1711
Open AccessBoron Bioavailability Revisited: From Plasma-Accessible Species to Microbiota-Accessible Complexes—Implications for Nutritional Essentiality
Boron (B) remains one of the least understood trace elements in human nutrition. Traditionally regarded as non-essential, its biological role has been reevaluated in light of emerging microbiome research. We provide a narrative synthesis of mechanistic, preclinical, and clinical studies to assess whether the colonic actions of B meet accepted criteria for nutritional essentiality. This review revisits B bioavailability through a dual-pathway framework distinguishing plasma-accessible boron (PAB)—small, fully absorbable species with transient systemic effects—from microbiota-accessible boron complexes (MABCs)—indigestible conjugates that reach the colon intact. Evidence indicates that PAB exerts short-term metabolic modulation, whereas MABCs act as prebiotic cofactors that stabilize microbial quorum sensing (autoinducer-2–borate; AI-2B), reinforce the colonic mucus barrier through borate–diol crosslinking, and support host–microbiota symbiosis. Deficiency or low intake of MABCs leads to dysbiosis, barrier fragility, and low-grade inflammation along gut–organ axes—effects reversible by MABC-rich diets. Analytical and clinical tools are proposed to discriminate between PAB and MABC pathways, including fecal B/speciation, AI-2B assays, and mucus-penetration markers. Recognizing B’s essentiality as a microbiota-dependent nutrient reframes its nutritional assessment, guiding future dietary guidelines and prebiotic design toward the microbiome–mucus interface.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (37) , 8270-8297
Trends on Potential Boron-containing Drugs by Advancements in Ligand-protein Crystals Complexes
Background: Boron-containing compounds (BCC) are attracting attention in drug design. Certain chemical features invite the exploration of efficacious interactions on known and potential drug targets for human use. Objective: The objective of this study is to analyze the reported crystal structure studies to determine trends resulting from the inclusion of boron atoms in potential drugs. Methods: Published data in the Protein Data Bank (PDB) with at least one BCC were analyzed; both ligands and targets were analyzed to describe the inferred or reported biological activity and the potential application as a drug in the treatment of human diseases. Results: Data from the PDB indicated targets for certain infectious diseases and cancers; however, potential treatments may extend to many other human pathologies as a consequence of the careful analysis of BCCs with proteins. All classes of enzymes and receptors have been crystallized with BCCs as ligands with most complexes demonstrating interactions in the regions known as relevant to protein function. Conclusion: The number of crystallized BCC-proteins complexes is increasing, and the variability of proteins expands the possibilities of medical applications. Currently, most systems are related to cancer growth and treatment, but deeper analysis may expand BCC utility and efficacy to many other chronic and degenerative diseases.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (37) , 8270-8297
Trends on Potential Boron-containing Drugs by Advancements in Ligand-protein Crystals Complexes
Background: Boron-containing compounds (BCC) are attracting attention in drug design. Certain chemical features invite the exploration of efficacious interactions on known and potential drug targets for human use. Objective: The objective of this study is to analyze the reported crystal structure studies to determine trends resulting from the inclusion of boron atoms in potential drugs. Methods: Published data in the Protein Data Bank (PDB) with at least one BCC were analyzed; both ligands and targets were analyzed to describe the inferred or reported biological activity and the potential application as a drug in the treatment of human diseases. Results: Data from the PDB indicated targets for certain infectious diseases and cancers; however, potential treatments may extend to many other human pathologies as a consequence of the careful analysis of BCCs with proteins. All classes of enzymes and receptors have been crystallized with BCCs as ligands with most complexes demonstrating interactions in the regions known as relevant to protein function. Conclusion: The number of crystallized BCC-proteins complexes is increasing, and the variability of proteins expands the possibilities of medical applications. Currently, most systems are related to cancer growth and treatment, but deeper analysis may expand BCC utility and efficacy to many other chronic and degenerative diseases.